Skip to main content
. 2019 Aug 19;8:207. doi: 10.1186/s13643-019-1126-1

Fig. 4.

Fig. 4

Evidence network for HBsAg loss for HBeAg-positive patients. ADV adefovir 10 mg daily, ETV entecavir, LAM lamivudine, TBV telbivudine, PLA placebo, TAF tenofovir alafenamide, TDF tenofovir disoproxil fumarate; ETVTDF, LAMADV1, and LAMADV2 code for different combinations of antiviral agents with full details in Additional file 3